BOEHRINGER-INGELHEIM
3.8.2022 12:07:11 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Unveils 2026 Customer Award Winners at Kinexions in Las Vegas4.6.2026 13:00:00 CEST | Press release
Global supply chain leaders recognized for delivering bold innovation, agility, and measurable impact Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the winners of its 2026 Customer Awards. Now in their eighth year, these awards were celebrated live at Kinexions North America, the flagship premiere global conference hosted by Kinaxis, bringing together supply chain leaders from around the world. The annual awards spotlight organizations and individuals who are redefining what’s possible in modern supply chains. The winners are driving innovation, responding with agility, and delivering real business results with the Kinaxis Maestro™ platform. The awards recognized seven leading companies including Reckitt, General Motors, Lupin, Jabil, and Cardinal Health among the full list of winners. Additionally, Praveen Vasudevan (Bio-Rad Laboratories) received the champion award for their industry contributions. “Kinexions is where the
STARTEEPO Invest Increases Stake in Xerox to More Than 6% Ahead of Q2 2026 Earnings4.6.2026 13:00:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to more than 6% of the Company’s outstanding common stock, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. Following the transaction, STARTEEPO beneficially owns approximately 8.0 million Xerox common shares and holds options on an additional 140,000 shares. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s third-largest shareholder. “We continue to view Xerox as a high-conviction investment and one of the largest positions in our portfolio,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. “Our conviction has increased as we continue to analyze the Company’s publicly available disclosures, strategic initiatives, and transformation efforts.” Increasing Conviction Ahead
Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology4.6.2026 10:10:00 CEST | Press release
Reply [EXM, STAR: REY] and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. The initiative brings together Reply’s expertise in building frontier generative models grounded in enterprise knowledge with the IEO’s clinical expertise and data assets to develop models tailored to highly complex oncology settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604488955/en/ Reply and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. As a first step, the IEO’s clinical teams and Information Systems department are working with a multidisciplinary Reply team with deep expertise in healthcare and LLM specialisation to define and prioritise the use cases that will guide development, while also map
UK AI Minister Kanishka Narayan Joins The AI Summit London as 10th Anniversary Agenda Expands Across Enterprise AI, Innovation and Policy4.6.2026 10:00:00 CEST | Press release
London Tech Week's flagship AI event will feature 300 speakers, live AI demonstrations, startup pitch competitions, executive training and the National AI Awards The AI Summit London today revealed the full agenda for its highly anticipated 10th anniversary edition, delivering its most expansive and future-focused programme to date. Taking place 10–11 June at Tobacco Dock as the headline AI event of London Tech Week 2026, the Summit expects more than 5,000 attendees, 300 speakers, 100+ sponsors and exhibitors, and a special executive presentation from Kanishka Narayan, Minister for AI and Online Safety, Department for Science, Innovation and Technology, across two days dedicated to the commercial realities and transformative potential of artificial intelligence. The 10th anniversary has been designed to move the conversation beyond experimentation and into enterprise-wide execution. New in 2026, the programme introduces The AI Impact Arena, delivering focused briefings and live demos,
Corona Launches 2026 Beach 100 Guide, Invites The World To Explore The Outdoors This Summer4.6.2026 10:00:00 CEST | Press release
Ahead of World Oceans Day, the global beach authority returns with a list of new locations, over 300,000 Tripadvisor experiences, and dedicated beach grants as part of its “This is Living” platform Corona, the world’s most valuable beer brand1, today announced the return of its annual global beach guide, the 2026 Corona Beach 100, ahead of World Oceans Day on June 8. The highly anticipated second edition spotlights 100 breathtaking and varied ocean-front destinations around the world while celebrating the natural ecosystems and local communities that help bring them to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604412899/en/ 2026 Corona Beach 100 - Legzira Beach, Morocco Connected to Corona’s “This Is Living” platform, which invites consumers to step outside and live life to the fullest this summer, the 2026 guide features 27 new beaches, hundreds of localized Tripadvisor travel experiences inspired by the world
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom